<?xml version="1.0" encoding="UTF-8"?><!-- Generated by Broadridge Transform (tm) - http://www.broadridge.com --><!-- Created: Wed Aug 12 20:30:23 UTC 2026 --><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:common="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001140361-24-046968</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001858703</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>3</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>06/30/2026</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001842952</issuerCik>
        <issuerName>Context Therapeutics Inc.</issuerName>
        <issuerCusips>
          <issuerCusipNumber>21077P108</issuerCusipNumber>
        </issuerCusips>
        <issuerPrincipalExecutiveOfficeAddress>
          <common:street1>2001 Market Street, Suite 3915</common:street1>
          <common:street2>Unit #15</common:street2>
          <common:city>Philadelphia</common:city>
          <common:stateOrCountry>PA</common:stateOrCountry>
          <common:zipCode>19103</common:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Blue Owl Capital Holdings LP</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>2934015.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>2934015.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2934015.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <classPercent>3.19</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
      <comments>The reported percentage is calculated based on 91,879,177 shares of Common Stock outstanding as of May 4, 2026, as reported on the Issuer's 10-Q filed with the Securities and Exchange Commission on May 6, 2026.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Context Therapeutics Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>2001 Market Street, Suite 3915, Unit #15, Philadelphia, PA 19103</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>This Statement is filed by Blue Owl Capital Holdings LP, referred to herein as the "Reporting Person."</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>399 Park Avenue, New York, New York 10022</principalBusinessOfficeOrResidenceAddress>
        <citizenship>See response to row 4 on the cover page hereto.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>N</notApplicableFlag>
        <typeOfPersonFiling>IA</typeOfPersonFiling>
      </item3>
      <item4>
        <amountBeneficiallyOwned>See response to row 9 on the cover page hereto.

Pursuant to Rule 13d-4 of the Act, the Reporting Person declares that filing this Statement shall not be deemed an admission that the Reporting Person is a beneficial owner of the reported securities, for purposes of Section 13(d) and/or Section 13(g) or for any other purpose.</amountBeneficiallyOwned>
        <classPercent>See response to row 11 on the cover page hereto.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>See response to row 5 on the cover page hereto.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>See response to row 6 on the cover page hereto.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>See response to row 7 on the cover page hereto.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>See response to row 8 on the cover page hereto.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>N</notApplicableFlag>
        <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Blue Owl Capital Holdings LP</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Karen Hager</signature>
        <title>Karen Hager / Chief Compliance Officer</title>
        <date>08/11/2026</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
